Certis Oncology Solutions for Drug Development
A growing tumor bank, customized models and a range of preclinical oncology services to inform better development decisions.
Preclinical Oncology Research & Development
At Certis Oncology Solutions, we develop custom orthotopic mouse models of specific human cancers, enabling the pharmacokinetic analysis of multiple therapies simultaneously. In preclinical drug development, our approach delivers more accurate, scientifically relevant data to improve lead optimization, reduce IND risk and expedite your path to clinical trials.
O-PDX: The Gold Standard for Translational Medicine
Scientific researchers have established that murine orthotopic patient-derived xenograft (O-PDX) models recapitulate the human tumor microenvironment far better than subcutaneous PDX and other commonly used models. Unlike other CROs, Certis brings extensive experience and deep scientific expertise in the orthotopic approach.
In-House MRI Capabilities Deliver a New Level of Precision
Certis owns one of the world’s only commercially available, small-scale magnetic resonance imaging (MRI) instruments. The resulting images, when paired with advanced analytical software, eliminate the need for dissection and remove variability from tumor measurements. When it comes to applying translational research to the development of novel cancer therapies, no laboratory service provider can match Certis Oncology Solutions.
Custom Solutions: Our Tumors or Yours
Our tumor bank of well-characterized, patient-consented tumors is rapidly growing. Certis collaborates with a number of industry leaders, private practices and hospital systems from which we source a broad array of tumor tissues and malignancies. Our scientists stand ready to expertly develop your custom orthotopic models using commercially available or client-supplied tissue or cell lines.
Certis conducts clinical research at our CLIA-certified, 7,000 square foot lab in Sorrento Valley, California. SCHEDULE A LAB VISIT: Info@certisoncology.com